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Abstract
Introduction—In an effort to improve prenatal screening for Trisomy 21, we evaluated
pregnancy associated plasma protein-A2 (PAPP-A2) as a potential novel second trimester
biomarker for Trisomy 21.
Methods—Trisomy 21 and normal control mid-trimester placental samples were subjected to
quantitative rt PCR analysis of seven genes we had previously found to be differentially expressed
in Trisomy 21 placentae. The localization and differential expression of PAPP-A2 in second
trimester placentae from normal and Trisomy 21 pregnancies was determined by
immunohistochemistry. PAPP-A2 maternal serum protein levels in ten Trisomy 21 and ten diploid
pregnancies were compared by Western blotting. Maternal serum PAPP-A2 levels were measured
in 30 Down syndrome cases and 142 normal controls, using ELISA. Regression analysis was used
to determine the correlation of PAPP-A2 with other existing markers of Trisomy 21.
Results—PAPP-A2 (aka PLAC3) mRNA and protein expression were both increased in Down
syndrome placentae as compared to diploid placentae. PAPP-A2 was also increased in maternal
serum from Down syndrome pregnancies as compared to diploid pregnancies. PAPP-A2
expression correlated weakly with established markers.
Discussion—This work takes advantage of our previously performed systematic approach to the
discovery of novel maternal serum biomarkers for Trisomy 21, using cDNA microarray analysis.
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Beginning with the validation of the microarray results, we have tracked PAPP-A2 overexpression
in Down syndrome from placental mRNA to maternal serum protein.
Conclusion—PAPP-A2 could serve as an additional maternal serum marker in prenatal
screening for Trisomy 21.
Keywords
Pregnancy associated plasma protein-A2; biomarker; Down syndrome; placenta; maternal serum;
second trimester
1. INTRODUCTION
Prenatal screening has evolved significantly in the past two decades with the introduction of
novel markers. Merkatz et al. was the first to identify an association between low maternal
serum concentrations of alpha-fetoprotein (AFP) and fetal Trisomy 21 (1). Before this
association, maternal age was the only known risk factor for an aneuploid pregnancy (2–4).
Subsequently, maternal serum AFP concentration combined with maternal age was part of
generally practiced prenatal screening protocol. Combining maternal age with AFP levels
the detection rate achieved was about 40% (1, 5). The quadruple test, which significantly
changed the landscape of prenatal screening comprises four maternal serum markers,
namely human chorionic gonadotropin (hCG) , Inhibin A, AFP and and uE3. Levels of hCG
and Inhibin A are elevated whereas levels of AFP and uE3 are decreased in Trisomy 21.(6–
10).
At a 5% false positive rate, in combination with maternal age, maternal serum markers can
detect approximately 70 to 80% of cases of Trisomy 21 and, by incorporating fetal
ultrasound measurements, slightly improved detection rates can be achieved (11, 12). The
issue of improved screening remains a priority due to the number of pregnant women
affected, residual risk and false positive rates, and the serious ramifications with respect to
reproductive health care (13–15). In the current study, we have evaluated the potential of
pregnancy associated plasma protein-A2 (PAPP-A2) as a novel biomarker for screening
pregnancies for Trisomy 21. PAPP-A2 is expressed abundantly in human placenta and in
non pregnant mammary gland and to a lower extent in various other tissues, including the
kidney, fetal brain and pancreas (16–18). It is known to cleave insulin growth factor binding
proteins IGFBP-4 and IGFBP-5 and has been found to be up-regulated in hypertensive
disorders associated with pregnancy, such as preeclampsia (19–21)
The current study builds on previous work that was based on a systematic approach to
discover better maternal serum markers of Trisomy 21, using microarray analysis of
Trisomy 21 and diploid placentae (22). Differential expression of placental proteins, because
of the highly vascularized nature of the placenta and its proximity to maternal circulation,
may be reflected in maternal serum and may be the basis of improved detection in prenatal
screening for Trisomy 21.
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2. METHODS
The current study was approved by the St. John’s University and Jacobi Medical Center
Institutional Review Boards.
2.1. Sample collection
Serum samples from the second trimester of normal and Trisomy 21 pregnancies were used
in the experiment. All the serum samples from normal pregnant women were collected by a
phlebotomist at Jacobi Medical Center, New York with informed consent and double IRB
approval (St. John’s University and Jacobi Medical Center IRBs) prior to amniocentesis or
CVS and concurrently with quad screening. Diagnoses were ultimately confirmed by
pregnancy outcomes. Serum samples from Trisomy 21 pregnancies were procured with
patient informed consent from the clinical laboratory Endoclab, Porto, Portugal with
permission obtained from Endoclab. Placental tissues were obtained from second trimester
voluntary terminations or spontaneous abortions at Jacobi Medical Center with appropriate
consent and IRB approval.
2.2. Quantitative real time reverse transcription polymerase chain reaction (RT-PCR)
Quantitative RT-PCR was performed to compare the expression levels of PAPPA2, ALDH7,
KISS1, PTTG1P, KRT8 and EST transcripts (id433020, id611475) in Trisomy 21 and normal
placental tissue, all previously found to be differentially expressed in microarray analysis of
Trisomy 21 placentae (22). Total RNA was extracted from the chorionic villi of human
placental tissues using an RNAeasy kit (Qiagen, Valencia, CA), after which quantitation and
purification assessment was performed using NanoDrop spectrophotometer (Thermo
scientific, USA) and Agilent 2100 Bioanalyzer (Agilent Technologies). The relative
expression levels of the above mentioned seven genes were assessed using quantitative RT-
PCR with an ABI PRISM 1500 Sequence Detection System (Perkin–Elmer, Foster City,
CA, USA). Equimolar amounts of total RNA from 7 Trisomy 21 and 7 diploid placentae
were reverse transcribed and amplified using a one step RT-PCR kit (Qiagen), according to
the manufacturer’s instructions. The GenBank access numbers of the genes are listed in
Table 1. The expression of the housekeeping gene GAPDH was also measured. Quantitative
RT-PCR was performed using 1 cycle for 10 min at 95° C then 40 cycles at 95°C for 30 sec,
60°C for 1 min and finally at 72°C for 30 sec. A standard curve was obtained for all 7 genes
using various dilutions and samples were measured in triplicate.
2.3. Immunohistochemistry
Placental tissue sections from 7 Trisomy 21 placentae and 7 diploid placentae were
deparaffinized with 100 per cent xylene (BDH-VWR) for 4 min, rehydrated with serial
alcohol solutions (100 to 70%) and washed in distilled water. The deparaffinized sections
were treated with 3%H2O2 for 30 min to quench endogenous peroxidase activity. Sections
were rinsed in distilled water and then microwaved in Antigen Retrieval Solution (8.2 mM
sodium citrate, 1.8 mM citric acid-pH 6.0, containing 0.01 per cent Triton X-100). After
subsequent washing with TBS-T (Tris-buffered saline with 0.1% Tween-20, pH 7.8),
sections were incubated in a humidified chamber and a 1:15 dilution of the primary
monoclonal anti-PAPP-A2 antibody (Sigma-Aldrich Corp. St. Louis, MO, USA) in TBS
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containing 1%bovine serum albumin and 0.2%Tween 20 overnight at 4° C. In negative
controls, serial sections were incubated with 1% BSA without the primary antibody. After
overnight incubation, the sections were washed in TBS containing 0.2%Tween 20 and
immunostaining was achieved using an avidin–biotin complex developer kit (Dako,
Carpinteria, CA, USA) and 3, 3-diaminobenzidine as a substrate. Sections were
counterstained with Mayer’s haematoxylin. The grading of immunohistochemistry staining
intensity was performed by three blinded observers by choosing the three most intensely
staining regions of chorionic villi, following a pre-defined scoring scheme established by a
practicing placental pathologist (SER). The inter-observer variability was tested among the
three observers and was found to be insignificant. .
These were graded based on a scale of 1 – 4 with 1 being the lightest staining and 4 being
the most darkly staining villi seen by each observer.
2.4. Western blotting
Protein concentrations of 10 Trisomy 21 maternal serum samples and 10 normal control
maternal serum samples were determined by performing a Bradford assay, using bovine
serum albumin as the standard. SDS sample buffer 4X (Invitrogen) was added to the
samples, which were denatured at 95°C for 4 min. Gel electrophoresis was carried out and
the proteins were separated using NuPAGE® Novex 3–8% Tris-Acetate Gels, 1.5 mm, 10
welled (Invitrogen, Carlsbad, CA). –Pure PAPP-A2 protein (R&D systems) was used as a
positive control. The proteins were then transferred to polyvinylidene difluoride membranes
(Invitrogen). The membranes were wetted with TBS-T (Tris-buffered saline with 0.1%
Tween-20, pH 7.8) for 10 min, and were blocked with Western blocker solution (Sigma) for
120 minutes. The membranes were then incubated with anti-PAPP-A2 primary antibody
(R&D systems),diluted to 0.66 µg/ ml (1:1500 dilution) in TBS-T. The membranes were
washed with TBS-T several times and incubated with secondary antibody, anti-rabbit IgG,
horseradish peroxidase-linked whole antibody (GE Healthcare, Buckinghamshire UK), at a
1:2500 dilution in western blocker solution at room temperature for 120 min. The
membranes were washed again with TBS-T three times for 10 min and treated with the ECL
Plus Western blotting detection system (GE Healthcare) and chemifluorescence was
detected by exposure to X-ray film (Kodak). Densitometric quantification of the Western
blot signal intensity of the bands was performed by densitometric analysis program image J
(from the NIH). The density values of albumin were used for normalization. For
immunoblotting of albumin, the membranes were washed again with TBS-T three times for
10 min and were stripped by incubating in stripping buffer (Thermo Scientific) at 50° C for
30 minutes. The Western blotting was carried out using albumin primary antibody (Sigma,
1:1000 dilution) according to the procedure described above.
2.5. Enzyme linked immunosorbent assay (ELISA)
PAPP-A2 concentrations were measured by a sandwich enzyme-linked immunosorbent
assay (ELISA) using a kit (Ansh labs) according to the manufacturer’s protocol.
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2.6. Statistical analysis
Differences of the parameters between the Trisomy 21 and diploid groups were analyzed by
two tailed Student’s t test. P<0.05 was considered as statistically significant. For PAPP-A2,
the median level at each completed week of gestation was calculated from the results of the
analyses in the control women’s serum samples. PAPP-A2 multiple of the median (MoM) is
obtained by measuring PAPP-A2 in maternal serum and comparing this value to the median
PAPP-A2 value at the same gestational age. Correlations of PAPP-A2 with markers of the
quadruple test were evaluated with linear straight-line regression analysis using the Pearson
correlation coefficient, P<0.05 was considered statistically significant. The intra-class
correlation coefficient analysis was used to measure the reliability of immunohistochemistry
grading data by blinded observers.
3. RESULTS
3.1. Differential expression of various genes measured by quantitative RT-PCR
Gross et al. previously performed gene expression profiling of placental tissue derived from
Trisomy 21 and normal pregnancies using whole-genome oligonucleotide microarrays (22).
Among several genes that were found to be differentially expressed in that study, we
specifically chose seven genes (Table 1) that had prominent differential expression and
performed quantitative RT-PCR analysis to compare the mRNA levels of these genes in
Trisomy 21 and normal placentae (n=7) . Relative levels of gene expression were quantified
based on standard curves after normalization to GAPDH. The association between gene
expression and Trisomy 21 (cases vs. controls) for each gene was calculated using the
Student’s t-test (p<0.05) .Based on the quantitative RT-PCR finding of 2.4-fold up-
regulation of PAPPA2 (aka PLAC 3) in Trisomy 21 placentae, we went on to evaluate the
potential of PAPP-A2 as a biomarker for prenatal screening. (Fig. 1)
3.2. Expression and localization of PAPP-A2 in normal and Trisomy 21 human placentae
The localization and expression pattern of PAPP-A2 in second trimester placentae from
normal and Trisomy 21 pregnancies was determined by immunohistochemistry. The
maternal characteristics associated with the placentas are shown in Table 2. Trisomy 21 and
normal human placental tissue sections were immunostained with anti-PAPP-A2 antibody
(Fig.2A–D). PAPP-A2 positive signals were detected in the cytoplasm of
syncytiotrophoblasts in the chorionic villi of both Trisomy 21 and normal pregnancies. This
observation suggests that the syncytiotrophoblasts are the prominent source of PAPP-A2
production in both Trisomy 21 and normal placentae. This finding regarding the localization
of PAPP-A2 in normal placenta is coherent with a previous report by Nishizawa et al. (19).
However the PAPP-A2 signal intensity (brown DAB stain) was clearly much stronger in the
syncytiotrophoblasts of Trisomy 21 placentae compared to normal placentae (Fig. 2A–D).
The specificity of PAPP-A2 was confirmed with use of negative controls and no staining
was observed (negative control not shown). PAPP-A2 expression was significantly
increased in the cytoplasm of syncytiotrophoblasts of Trisomy 21 placentae relative to
normal placentae (p<0.05, Fig. 2E).
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3.3. Elevated levels of PAPP-A2 protein in maternal sera of Trisomy 21 pregnancies
After confirming increased PAPP-A2 expression in Trisomy 21 placenta with the
immunohistochemistry study we next looked at the levels of PAPP-A2 in the second
trimester maternal sera of Trisomy 21 and normal pregnancies using Western blotting (Fig.
3A). Serum levels of PAPP-A2 were significantly higher in Trisomy 21 pregnancies
compared to uncomplicated pregnancies (mean immunoblot band density on 0 to 1 scale of
0.58 for Trisomy 21 samples vs. 0.34 for normal control samples, p<0.05) (Fig. 3B). All the
sera used in this experiment were collected from second trimester pregnancies. The band
intensities were measured using the image J software from the NIH and the relative band
intensity, i.e. the ratio of PAPP-A2 band intensity to albumin band intensity was taken into
consideration for statistical analysis.
3.4. Concentration of PAPP-A2 in Trisomy 21 and normal pregnancies at various weeks of
gestation
We next determined PAPP-A2 protein levels in maternal sera from women with Trisomy 21
pregnancies (n=30) and normal pregnancies (n=142) at various weeks of gestation. A
sandwich ELISA system was used for the evaluation of the serum concentrations of PAPP-
A2. The maternal characteristics of the study population are provided in Table 3. The levels
of PAPP-A2 increased with gestational age both in normal (NS) and Trisomy 21 (DS)
maternal serum samples (Fig. 4A). Only mid-trimester samples were used for comparisons
between DS and NS. The mean PAPP-A2 was 1.53 MoM in Trisomy 21 samples as
compared to normal samples between 15 and 20 weeks of gestation (Fig. 4B). The mean
concentration of PAPP-A2 between 15 and 20 weeks was 82.70±12.13 ng/ml in aneuplioid
pregnancies compared to 56.35±3.63 ng/ml in normal pregnancies. This difference between
Trisomy 21 and diploid pregnancies was statistically significant (p<0.05).
3.5. Correlation of PAPP-A2 with markers of quadruple test
Regression analysis was used to determine if there was any association of PAPP-A2 with
other markers of Trisomy 21 in second trimester normal maternal serum samples. Levels of
the Trisomy 21 markers AFP, uE3, hCG, and inhibin-A were obtained from the results of the
quadruple test that pregnant women undergo in the second trimester. The Pearson
correlation coefficient (r) value was 0.104 for AFP (Fig. 5A), 0.032 for uE3 (Fig. 5B), 0.327
for hCG (Fig. 5C), 0.289 for inhibin (Fig. 5D). The findings of this correlation study
demonstrate that at 15–20 weeks of gestation, the maternal serum PAPP-A2 levels in normal
pregnancies are not significantly correlated with the levels of AFP and uE3 (P>0.05) .
However there is significant correlation of PAPP-A2 with hCG and Inhibin (P<0.05).
4. DISCUSSION
Prenatal screening using maternal serum markers has been in practice for over two decades
now and despite current international research efforts the detection rate of Trisomy 21
pregnancies using the quadruple test remains close to only 75%. This detection rate could be
improved significantly with additional biomarkers with high sensitivity and specificity (3,
24). In the current study we have evaluated in a small scale the potential of PAPP-A2 as a
novel biomarker for screening pregnancies for Trisomy 21. Our study is based on a previous
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microarray study by Gross et al. on Trisomy 21 and normal placentae that revealed
differential expression of certain genes (22). Among these differentially expressed genes we
chose seven that had prominent differential expression and validated the microarray findings
using quantitative RT-PCR. Our preliminary RT-PCR study findings substantially support
the results from the microarray study. The mRNA levels of PAPPA2 were strikingly higher
in Trisomy 21 pregnancies as compared to normal pregnancies. Although there was another
expressed sequence tag that showed prominent up-regulation of mRNA by about 2.5 fold,
we were particularly interested in looking at PAPP-A2, due to its functional and structural
similarity to PAPP-A, an existing biomarker for Down syndrome (25).
After confirming the microarray results with RT-PCR, we performed immunohistochemical
analysis of second trimester Trisomy 21 and normal human placentae. In the second
trimester of pregnancy it was observed that PAPP-A2 is expressed in the synctiotrophoblast
layer of the placental villi (Fig. 2A–D) in coherence with previous studies on PAPP-A2
localization in the first trimester (23). In our immunohistochemistry study we, for the first
time, have found that PAPP-A2 is prominently up regulated in Trisomy 21 placentae when
compared to normal placentae (Fig. 2E). Our immunohistochemical results substantiate our
RT-PCR findings.
Although we have shown differential up regulation of PAPP-A2 at the mRNA level and at
the protein level in the syncytiotrophoblasts of placental tissue, it was vital to show that
levels of PAPP-A2 were elevated in the maternal sera from Trisomy 21 pregnancies as
compared to uncomplicated pregnancies, if the potential of PAPP-A2 as a maternal serum
marker was to be considered. We therefore performed Western blot analysis on second
trimester maternal serum samples and showed that PAPP-A2 levels were significantly
elevated in Trisomy 21 pregnancies. Furthermore, our investigation of maternal serum levels
of PAPP-A2 in second trimester Trisomy 21 and normal pregnancies with ELISA further
support our hypothesis that the increase in expression of placental PAPP-A2 protein is
reflected in maternal serum (Fig. 4B–C).
Multiple factors can contribute to inter individual variation of PAPP-A2 levels. In our study,
the gestational age of the subjects was determined according to the last menstrual period and
in most cases was confirmed by ultrasound. However, in cases that were not confirmed by
ultrasound there is the chance of a subject providing an incorrect date of her last menstrual
period at the time of sample collection. Also it needs to be pointed out that the storage time
for the Trisomy 21 serum samples was longer than that of the normal samples.
Consequently, small differences in levels of PAPP-A2 found in Trisomy 21 serum samples
may at least in part reflect the longer storage time for those samples. There is a possibility
that the increase in PAPP-A2 levels in Trisomy 21 samples might be more pronounced if
fresh samples were used. One of the major limitations of our study is that the adjustment for
PAPP-A2 levels was only made for gestational age but not ethnicity or maternal weight.
Multiple regression analysis with larger samples containing various ethnicities at different
weeks of gestation can be done to define the contribution of maternal variables that
influence the measured concentration of PAPP-A2. Studies are also needed to determine the
interactions among these covariates. In addition, we also found that in normal pregnancies,
there is no or weak association between levels of PAPP-A2 and levels of currently used
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maternal serum markers. These correlation studies support the hypothesis that PAPP-A2, as
a fifth marker, may substantially improve upon the currently used quadruple test.
In the current work, we have demonstrated increased levels of PAPP-A2 in Trisomy 21
pregnancies compared to uncomplicated pregnancies in the mid-trimester. Future larger
scale studies are needed to establish the sensitivity and specificity of this novel biomarker.
Such studies would also measure the incremental gain in detection using a “quint” test that
includes PAPP-A2 in comparison to the existing quadruple test. In recent years, prenatal
screening has been dominated by first trimester screening and, very recently, by non-
invasive prenatal testing (NIPT). Although we focused on expression of PAPP-A2 in the
mid-trimester in the current work, a future direction for this research would be to evaluate
PAPP-A2 as a potential first trimester biomarker for aneuploidy. An analysis of costs and
outcomes of NIPT for Trisomy 21 using cell free fetal DNA in the UK National Health
Service concluded that, as first line testing, although NIPT was likely to be more sensitive
than conventional prenatal screening, it would be more costly. Further research was needed
to see how it would fare in “real world” conditions (26). Despite the recent advances in the
field, mid-trimester prenatal screening will continue to add value, especially in cases of
borderline first trimester screening results, in multiple gestations and in parts of the world
where NIPT remains unaffordable.
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Highlights
• Expression of PAPPA2 and the protein it encodes are elevated in Down
syndrome placentae.
• Up-regulation of PAPP-A2 in Down syndrome placentae is reflected in maternal
serum.
• PAPP-A2 correlates weakly with two existing markers for aneuploidy.
• Elevated PAPP-A2 is a potential novel biomarker for Down syndrome.
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Fig. 1.
Differential expression of various genes in Trisomy 21 placentae (n=7) . Results are
expressed as fold changes in Trisomy 21 placentae compared to normal placentae. mRNA
levels are normalized to GAPDH. Error bars refer to standard deviations. All samples were
run in triplicate.
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Fig. 2.
PAPP-A2 immunohistochemical staining in diploid and Trisomy 21 placentae.
Representative immunohistochemistcal staining of PAPP-A2 in second trimester normal
(n=7, A, C) and diploid placentae (n=7) at 200× (A, B) and 400× (C, D). Prominent staining
is apparent in the cytoplasm of syncytiotrophoblasts. Signal intensity is much stronger in
Trisomy 21 placentae (B, D) as compared to normal placentae (left). Significantly increased
PAPP-A2 expression (p<0.05) was seen in the cytoplasm of syncytiotrophoblasts of
Trisomy 21 placentae (n=7) relative to normal placenta (n=7) in the second trimester (E).
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Fig. 3.
Western blot analysis of PAPP-A2 in maternal sera from second trimester Trisomy 21 (DS,
n=10) and normal (NS, n=10) pregnancies (A). The band intensities were measured using
image J software from the NIH and normalized to albumin. Serum levels of PAPP-A2 were
significantly elevated in Trisomy 21 pregnancies compared to uncomplicated pregnancies
(B) (p<0.05).
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Fig. 4.
Scatter plot of concentration of PAPP-A2 (ng/ml) versus weeks of gestation in normal (NS)
and Trisomy 21 (DS) maternal serum (A). Box plot representing concentrations of PAPP-A2
(ng/ml) between 15 and 20 weeks of gestation in normal (NS) and Trisomy 21 (DS)
maternal serum (B).
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Fig. 5.
Correlation of [PAPP-A2] with other maternal serum markers. The Pearson correlation
coefficient (R) value was 0.104 for AFP (A), 0.032 for uE3 (B), 0.327 for hCG (C), 0.289
for inhibin (D) in normal maternal serum samples at 15–20 weeks of gestation.
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Table 2
Maternal characteristics of the study population (placental specimens)
Maternal Characteristic DS (n=7) NS (n=7)
Age range (Years)
Median Age
22–40
39
19–35
29
Mean Gestational age (Weeks) 18± 0.81 19.7± 2.21
Ethnic origin 85.72% White
14.28% African American
42.85% Hispanic
42.85% African American
14.28% White
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Table 3
Maternal characteristics of the study population (serum specimens)*
Maternal Characteristic DS (n=30) NS (n=142)
Age range (years) 22–40
(median 31, p>0.05 compared to NS)
17–43
(median 30)
Weight range (lbs) 93–307 101–309
Gestational age (weeks) 13.65 ± 2.69 (Overall study)
(p>0.05 compared to NS)
16.45±1.61 (15–20 weeks)
(p>0.05 compared to NS)
16.69 ± 2.04 (Overall study)
17.25±1.38 (15–20 weeks)
Ethnic origin 100% Portuguese 49.29% Hispanic
34.5% African American
15.74% Pacific Island
3.52% White
1.4% American Indian
2.81% Other
*
There were no significant differences in maternal age, weight or gestational age between the two study populations. However the ethnic origins
between the groups were different, as discussed in text.
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